P1008 Subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab

Moens, A; Holvoet, T; Bossuyt, P; Lobaton, T; Posen, A; Cremer, A; Capirchio, L; Caenepeel, C; Lambrecht, G; Amezaga, AJ; Reenaers, C; Peeters, H; Willandt, B; Deprez, N; De Rechter, J; Arijs, I; Straetemans, N; Dreesen, E; Ferrante, M

doi:10.1093/ecco-jcc/jjae190.1182

P1008 Subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab

Author:

Moens, A

Holvoet, T ; Bossuyt, P ; Lobaton, T ; Posen, A ; Cremer, A ; Capirchio, L ; Caenepeel, C ; Lambrecht, G ; Amezaga, AJ ; Reenaers, C ; Peeters, H ; Willandt, B ; Deprez, N ; De Rechter, J ; Arijs, I ; Straetemans, N ; Dreesen, E ; Ferrante, M

Keywords:

Science & Technology, Life Sciences & Biomedicine, Gastroenterology & Hepatology, 1103 Clinical Sciences, 3202 Clinical sciences

P1008 Subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab

Author:

Keywords:

About us

Our services

Our solutions